Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4174 - A phase I dose-escalation study of the novel peptide ALM201 in patients (pts) with advanced solid tumours

Date

11 Sep 2017

Session

Poster display session

Presenters

Aya El-Helali

Citation

Annals of Oncology (2017) 28 (suppl_5): v122-v141. 10.1093/annonc/mdx367

Authors

A. El-Helali1, R. Plummer2, G. Jayson3, V. Coyle1, Y. Drew2, N. Mescallado4, N. Harris2, A. Clamp4, J. McCann5, R. Kennedy6, A. Cranston7, R. Wilson1

Author affiliations

  • 1 Medical Oncology, Centre for Cancer Research and Cell Biology, BT9 7JL - Belfast/GB
  • 2 Medical Oncology, Northern Institute for Cancer Research, Newcastle upon Tyne/GB
  • 3 Division Of Molecular & Clinical Cancer Sciences, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 4 Oncology, Institute of Cancer Sciences and Christie Hospital, Manchester/GB
  • 5 Patient Advocacy, Northern Ireland Cancer Research Consumers Forum, Belfast/GB
  • 6 Almac Diagnostics, Almac Diagnostics, Craigavon/GB
  • 7 Drug Discovery, Almac Discovery, Craigavon/GB
More

Resources

Abstract 4174

Background

ALM201 is a novel 23-amino acid peptide derived from FKPB-L, a human endogenous protein with inherent anti-angiogenic activity. Pre-clinically, ALM201 potently inhibits cell migration, invasion and neo-vessel formation without effects on cell cycle or proliferation.

Methods

We enrolled pts with solid tumours using a single patient (10 - 40mg) then 3 + 3 (80 - 300mg) dose escalation design. ALM201 was administered subcutaneously (S.C.) once daily on days 1-5, 8-12, and 15-19 every 21 days. All pts continued until disease progression (PD) or dose-limiting toxicity (DLT). Primary objectives were to determine the safety, tolerability and recommended phase II dose (RP2D) of ALM201. Secondary objectives were to determine the pharmacokinetics (PK) and anti-tumour activity. Plasma and urine samples were analysed by a validated LC-MS/MS method.

Results

We report interim data in 18 evaluable pts enrolled in 8 dose levels. Cancers included ovarian (5), colorectal (4), NSCLC (2), endometrial (1), gallbladder (1), cervical (1), urachal (1), renal (1), pancreatic (1) and mesothelioma (1). Doses of 10 - 300mg were well tolerated. No DLTs were observed. The only toxicity was grade 1 injection site skin reaction. Median treatment duration was 11.1 weeks (range 3-18 wks). Two patients had stable disease for up to 6 cycles prior to progression. Maximal plasma concentrations were typically observed 1.5h (0.75-4h) after dosing indicating fairly rapid absorption. Above 40mg, plasma concentrations were consistently seen up to 6h after dosing (assay LLOQ = 100ng/mL). Where the terminal phase could be defined, half-lives

Conclusions

Monotherapy ALM201 administered S.C. demonstrated a very good safety profile and acceptable PK in patients with advanced solid tumors. The RP2D analysis is currently ongoing.

Clinical trial identification

EudraCT No: 2014-001175-31

Legal entity responsible for the study

Almac Discovery

Funding

Almac Discovery and Invest Northern Ireland

Disclosure

R. Kennedy: Employee at Almac Diagnostics & Almac Group. A. Cranston: Employee at Almac Discovery. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.